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Abstract
Background: Understanding the interactions between tumor and the host immune system is critical to finding
prognostic biomarkers, reducing drug resistance, and developing new therapies. Novel computational methods are
needed to estimate tumor-infiltrating immune cells and understand tumor–immune interactions in cancers.
Results: We analyze tumor-infiltrating immune cells in over 10,000 RNA-seq samples across 23 cancer types from
The Cancer Genome Atlas (TCGA). Our computationally inferred immune infiltrates associate much more strongly
with patient clinical features, viral infection status, and cancer genetic alterations than other computational
approaches. Analysis of cancer/testis antigen expression and CD8 T-cell abundance suggests that MAGEA3 is a
potential immune target in melanoma, but not in non-small cell lung cancer, and implicates SPAG5 as an
alternative cancer vaccine target in multiple cancers. We find that melanomas expressing high levels of CTLA4
separate into two distinct groups with respect to CD8 T-cell infiltration, which might influence clinical responses to
anti-CTLA4 agents. We observe similar dichotomy of TIM3 expression with respect to CD8 T cells in kidney cancer
and validate it experimentally. The abundance of immune infiltration, together with our downstream analyses and
findings, are accessible through TIMER, a public resource at http://cistrome.org/TIMER.
Conclusions: We develop a computational approach to study tumor-infiltrating immune cells and their interactions
with cancer cells. Our resource of immune-infiltrate levels, clinical associations, as well as predicted therapeutic
markers may inform effective cancer vaccine and checkpoint blockade therapies.
Keywords: Cancer immunity, Tumor immune infiltration, Cancer immunotherapies, Cancer vaccine, Checkpoint
blockade
Background
Cancer immunotherapy has recently achieved remarkable
success in treating late stage tumors [1, 2], but a substan-
tial fraction of patients failed to respond [3, 4]. Efforts
have been made to elucidate the tumor–immune interac-
tions [5–8] and provide prognostic predictors [9–11].
Rooney et al. [6] studied cytolytic activity (CYT) using the
expression levels of two effector molecules and identified
possible mechanisms of immune evasion. Another recent
work [7] characterized the immunophenotypes in colorec-
tal cancer and provided novel therapeutic targets. While
these studies profoundly improved the understanding of
cancer immunoediting [12], less is known about how the
interactions between tumor and the immune system im-
pact patient outcome. Clinical investigations on tumor-
infiltrating immune cells have established the roles of
cytotoxic T cells (CTLs) and tumor-associated macro-
phages (TAMs) in some diseases [13, 14]. However, the
clinical impact of other immune cells in many cancers re-
mains poorly understood. Hence, there is a great need for
a more comprehensive and translational analysis of tumor
immunity to better understand the multi-component
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antitumor response and guide effective immunotherapies
in different cancers.
In this work, we integrated the molecular profiles of
over 10,000 tumor samples across 23 cancer types to in-
vestigate the impact of individual immune components
on a wide spectrum of clinical features. Our estimates of
tumor-infiltrating immune cells were validated using
multiple approaches, including in silico simulation, com-
parison with orthogonal inferences, and a pathological
approach. Correlating immune infiltration with patient
outcomes, we identified a number of associations, in-
cluding both novel associations and those supported by
prior studies [14]. Our analysis also suggested that the
inter-tumor heterogeneity of immune infiltration is po-
tentially caused by both cancer genetic variations as well
as the disease-specific expression pattern of the chemo-
kine/receptor network. As a translational approach, we
investigated immunotherapy targets for both therapeutic
cancer vaccine and checkpoint blockade. Finally, our in
silico inferences and associated findings have been pack-
aged into a web-accessible resource, TIMER (Tumor IM-
mune Estimation Resource), to enable further explorations
of the disease-specific clinical impact of different immune
infiltrates in the tumor microenvironment.
Results
Computational estimation of tumor immune infiltration
We developed a computational method to estimate the
abundance of six tumor-infiltrating immune cell types (B
cells, CD4 T cells, CD8 T cells, neutrophils, macrophages,
and dendritic cells) to study 23 cancer types in The Cancer
Genome Atlas (TCGA): adenocortical carcinoma (ACC),
bladder carcinoma (BLCA), breast carcinoma (BRCA), cer-
vical squamous carcinoma (CESC), colon adenocarcinoma
(COAD), diffusive large B-cell lymphoma (DLBC), glio-
blastoma multiforme (GBM), head and neck carcinoma
(HNSC), kidney chromophobe (KICH), kidney renal clear
cell carcinoma (KIRC), kidney renal papillary cell carcin-
oma (KIRP), lower grade glioma (LGG), liver hepatocellu-
lar carcinoma (LIHC), lung adenocarcinoma (LUAD), lung
squamous carcinoma (LUSC), ovarian serous cystadeno-
carcinoma (OV), prostate adenocarcinoma (PRAD), rec-
tum adenocarcinoma (READ), skin cutaneous melanoma
(SKCM), stomach adenocarcinoma (STAD), thyroid car-
cinoma (THCA), uterine corpus endometrial carcinoma
(UCEC), and uterine carsinosarcoma (UCS). These six
immune cell types include some of the currently most
promising cancer immunotherapy targets and also have
sufficient numbers of reference immune cell samples to
make accurate inferences (“Methods”). The prerequisite
data include tumor purity, tumor gene expression profiles
(as transcript per million reads (TPM)) from TCGA, and
an external reference dataset of purified immune cells.
Tumor purity is critical to selecting genes informative for
deconvolving immune cells in the tumor tissue and was
inferred from copy number alteration data using an R
package, CHAT, we have developed [15] (Fig. 1a). Our
purity estimation method has been validated using diluted
series with known tumor/normal mixture ratios and
agreed with previous methods and orthogonal estimations
[16]. The distributions of tumor purity showed large varia-
tions among different samples across most of the 23
TCGA cancer types (Additional file 1: Figure S1). For each
cancer dataset, batch effects between TCGA and the ex-
ternal reference data sets were removed using ComBat
[17] (Fig. 1b). Next we selected genes whose expression
levels are negatively correlated with tumor purity (Fig. 1c;
Additional file 1: Figure S2; Additional file 2: Table S1), an
indication that these genes are expressed by stromal cells
in the tumor microenvironment. Across all 23 cancers, in-
formative genes selected from the above steps are signifi-
cantly enriched for a predefined immune signature [18]
(Fig. 1d). This result indicates that large numbers of im-
mune cell-specific genes are highly expressed in the tumor
microenvironment. Finally, we used constrained least
squares fitting [19] on the informative immune signature
genes to infer the abundance of the six immune cell types
(Fig. 1e).
As a key component of TIMER, the outcome of the
above method was validated with multiple approaches.
The first one was pathology, where we estimated the
levels (low, median, and high) of neutrophils in bladder
cancer samples using hematoxylin and eosin stained
slides from TCGA (“Methods”). Our in silico predictions
of neutrophil abundance agreed well with the histo-
logical estimations (Additional file 1: Figure S3a, b). We
also validated our predictions using total infiltrating leu-
kocytes estimated from DNA methylation data [20] and
observed high concordance between our RNA and the
DNA-based predictions in all available cancers (Additional
file 1: Figure S3c). In addition, Monte Carlo simulations
with known immune cell fractions were applied to all can-
cer types. High correlations were observed between the
predicted and simulated immune cell abundance for all
comparisons except CD4, CD8 T cells, dendritic cells in
GBM, and B cells in DLBC (Additional file 1: Figure S3d;
“Methods”), which were excluded from downstream ana-
lysis. The inferred relative fractions of the six immune cell
types of all the samples across 23 cancers are available in
Additional file 3: Table S2.
Clinical relevance of tumor immune infiltration
To study the distribution of infiltrating immune cells in
the tumor and adjacent/normal tissues, we focused on
18 cancer types for which the mRNA expression profiles
of adjacent or normal tissues were available. Consistent
with Rooney et al. [6], CD8 T cells are enriched in tumor
tissues in kidney cancer (KIRC) and head and neck
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cancer. In contrast, CD8 T cells appear to be in lower
abundance in most other cancers, such as non-small cell
lung carcinomas (including adenocarcinoma and squa-
mous cell carcinoma) and colorectal cancer (including
colon and rectal adenocarcinoma) (Fig. 2a). Macrophages
are significantly enriched in GBM, which is supported
by previous observations showing that microglia and
macrophages are present in large numbers in the glioma
microenvironment [21]. Furthermore, the abundance of






Fig. 1 Computational method for estimating the abundance of tumor-infiltrating immune cells. Tumor purity was estimated for each sample
using DNA single-nucleotide polymorphism (SNP) array data (a). B allele frequency (BAF) is the frequency of a randomly selected parental allele.
The logR ratio (LRR) is the log2(Y/2), Y being the marker intensity in the SNP array. TCGA gene expression profiles were combined with reference
immune cell expression data after batch effect removal (b). Informative genes with expression levels inversely correlated with tumor purity (Pearson’s
r≤−0.2 and P value≤ 0.05) are selected (c) and tested for immune signature enrichment (Fisher’s exact test) (d). In all 23 cancers informative genes
are significantly enriched for immune signature. Diffuse large B-cell lymphoma (DLBC) has the lowest enrichment (odds ratio = 1.6, q = 0.0005, Fisher’s
exact test). In this study, we estimate the abundance of six immune cell types (B cells, CD4 T cells, CD8 T cells, neutrophil, macrophage, and dendritic
cells) using selected immune signature genes through constrained least squares fitting (e). Asterisks in d indicate event significance at a 1 % false
discovery rate
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Fig. 2 Distribution of infiltrating immune cells and selective enrichment of B cells in the tumor microenvironment. a The abundance of
infiltrating CD8 T cells, macrophages, and B cells in 18 cancer types, with both primary tumor and adjacent (Adj)/normal (Norm) tissue available.
Normal tissue was from healthy donors where adjacent tissues were unavailable. Statistical significance was evaluated by Wilcoxon rank sum test.
Blue arrowheads point to three cancers with B cells significantly enriched in the primary tumor and associated with clinical outcomes. q values are
colored red, blue, or black for significant (false discovery rate≤ 0.15) enrichment in tumor, adjacent or normal tissue, or insignificance, respectively.
b B-cell infiltration level significantly predicted patient survival in selected cancer types. Tumors in the top 20th percentile of B-cell infiltration
were compared with those in the bottom 20th percentile. The median survival time for the top 20 % of patients with brain, lung, and bladder
cancers was 460, 1778, and 2000 days, respectively, and for the bottom 20 % 345, 976, and 575 days, respectively. Statistical significance and
hazard ratios (HR) with 95 % confidence intervals were calculated for all the samples, not just the top and bottom 20 %, using multivariate Cox
regression including all six immune cell types, patient age, and clinical stage
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the adjacent or normal tissues in eight cancer types.
Interestingly, B-cell infiltration predicts a significantly
better outcome in a subset of these cancers (Fig. 2b).
The most dramatic case is GBM, where patients with
the top 20 % of B-cell infiltration have a 4.7-month lon-
ger median survival time than those with the lowest
20 % (“Methods”). This result suggests that tumor-
infiltrating B cells play an important role in the antitu-
mor responses in GBM and lung and bladder cancers.
We next investigated how infiltrating immune cells in-
fluence clinical outcomes. Using multivariate Cox regres-
sion adjusted for age, stage, and viral infection status, we
identified many significant associations between immune





Fig. 3 Immune cell infiltration predicts clinical outcome. a Association of tumor infiltrating immune cells with patient survival. For each cancer
type, multivariate Cox regression was performed, with covariates including the abundance of six immune cell types, patient age at diagnosis,
clinical stage, and viral infection status when available. Each entry on the first six rows of the heatmap represents the hazard ratio (HR) of a
corresponding immune cell type, with larger size indicating statistical significance at a false discovery rate (FDR) of 0.15 and color indicating the
value of the HR. The last row of the heatmap records the Cox model HRs and statistical significance using cytolytic activity (CYT) scores adjusted
for the same covariates. Multiple test correction was performed using q value across cancer types and six immune components. b Kaplan–Meier
curves of melanoma (SKCM) and head and neck cancer (HNSC) stratified by infiltration CD8 T-cell abundance. Median survival time for the top
20 % of patients in melanoma and head and neck cancers is 4507 and 1838 days, respectively, and for bottom 20 % 2005 and 862 days, respectively.
Statistical significance, hazard ratios, and 95 % confidence intervals were calculated using multivariate Cox regression and all the samples as described
above. c CD8 T-cell infiltration in primary tumors (metastatic samples for SKCM) significantly (FDR≤ 0.15) predicts tumor relapse in selected cancers.
Statistical significance was evaluated using logistic regression correcting for patient age and clinical stage
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T-cell infiltration associates with prolonged survival and
macrophage infiltration consistently predicts worse out-
come, other immune cell types have cancer-specific effects
on prognosis (Fig. 3a). These observations corroborate
previous reports that cytotoxic T-cell infiltration inde-
pendently predicts better outcome in liver [22] and rectal
[23] cancers. Consistent with established knowledge in
melanoma and head and neck cancer [24, 25], we also
found infiltrating CD8 T cells to be associated with sur-
vival in univariate analysis (Fig. 3b). However, it is not an
independent predictor of better outcome after adjusting
for other covariates, since CD8 T cells are correlated with
neutrophil infiltration in melanoma and human papilloma
virus (HPV) infection in head and neck cancer
(“Methods”). In fact, infiltrations of B cells and CD4 and
CD8 T cells are all significantly higher in HPV-positive
than in HPV-negative head and neck tumors (Additional
file 1: Figure S4), suggesting that viral antigens result in an
elevated lymphocyte response. Besides the effect on pa-
tient survival, CD8 T cells may also play an important role
in preventing tumor recurrence (Fig. 3c). In melanoma
and colorectal and cervical cancers, patients with higher
CD8 T-cell infiltration in the primary tumors have a sig-
nificantly lower risk of developing a second tumor during
the follow-up period. Overall, our observations on tumor-
infiltrating CD8 T cells are extensively supported by clinical
studies [14] (Additional file 4: Table S3), thus providing
additional validation to our deconvolution method.
Cytolytic activity (CYT) is a previously defined metric
of immune-mediated cell destruction [6]. Compared
with CYT, our analysis identified many more strong as-
sociations between tumor-infiltrating immune cells and
patient clinical outcomes (Fig. 3a), presumably because
our method takes into account expression data from
hundreds of genes instead of only two.
TAM numbers have been reported to be a predictor of
worse outcome in many cancers [13]. Consistently, we
found that TAM significantly associates with worse out-
come in bladder, breast, and ovarian cancers and in
lower-grade glioma (Fig. 3a), supporting TAMs as an in-
dependent prognostic factor for these cancers. Extending
this analysis to the less well-studied chromophobe renal
carcinoma (KICH), we detected a significant inverse as-
sociation between macrophage infiltration and patient
survival (Fig. 3a), suggesting that TAMs function in
KICH as in other solid tumors.
Potential causes for immune infiltration heterogeneity
We next examined the possible causes of inter-tumor
immune infiltration heterogeneity, such as somatic mu-
tations and chemokine expression. Non-synonymous
somatic mutations in the tumor genome can generate
immunogenic neoantigens that trigger antitumor re-
sponse through T-cell activation [26–29]. In addition,
total mutation load has been suggested as a surrogate
for neoantigen count [6]. To understand how the host
immune system responds to tumor somatic mutations,
we studied the association of infiltrating immune cells
and total mutation load. Tumor purity is a confounding
factor in this analysis, since purity affects the power to
detect somatic mutations [20] and drives the pattern of
gene expression [16]. After correcting for purity, we ob-
served positive correlations between the total mutation
count and infiltrating immune cells in a subset of can-
cers (Fig. 4a). In lung squamous cell carcinoma, lower
grade glioma, HPV-negative head and neck cancer, and
prostate cancer, CD8 T-cell infiltration increases signifi-
cantly with tumor mutation load, in support of a previ-
ous study [6]. In addition, we observed that dendritic
cell infiltration is correlated with the total mutation load
in breast cancer (Spearman’s ρ = 0.11, q = 0.037), as is B-
cell infiltration (ρ = 0.13, q = 0.018), suggesting cancer-
specific roles for these cell types in antitumor immunity.
Similar associations were observed when we used neoan-
tigen load estimated from a previous work [6] instead of
total mutation load (Additional file 1: Figure S5), cor-
roborating our conclusion that increased tumor neoepi-
tope load elevates the infiltration of multiple immune
cell types.
Besides point mutations, microsatellite instability (MSI)
is seen in colorectal, stomach, and endometrial cancers.
MSI typically generates small indels across the genome,
producing non-self antigens that may be recognized by
the host immune system. Consistent with a previous re-
port [7], we found CD8 T cells to be significantly more
abundant in MSI-high (MSI-H) tumors compared with
MSI-low (MSI-L) tumors in colon cancer (Fig. 4b).
Among the remaining three TCGA cancers with available
MSI information, we also found higher levels of MSI to be
associated with increased CD8 T cells in stomach cancer.
A recent study reported that MSI-high colon cancer pa-
tients showed significantly better responses to PD-1 block-
ade therapies [12] and our results suggest that this
conclusion may be extended to other gastro-intestinal
cancers with MSI.
To further investigate the regulation of immune infil-
trates in different cancers, we also systematically studied
the expression levels of chemokines and receptors. Most
of these molecules were expressed in the microenviron-
ment (Additional file 1: Figure S6a, b). CD8 T-cell level
is significantly associated with a subset of chemokine–
receptor pairs, including CCL3,4,5–CCR1,5 and XCL1,2–
XCR1 (Fig. 4c). On the other hand, different molecules are
associated with macrophage abundance in cancer-specific
patterns. Macrophage infiltration appears to be related to
CXCL12–CXCR4 in thyroid, head and neck, stomach, and
colon cancers and to CCL14,CCL23–CCR1 in lung can-
cers (Fig. 4d). Our results highlight potential bases for
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inter-tumor heterogeneity in immune cell infiltration and
suggest possible means for reducing macrophage recruit-
ment to the tumor microenvironment.
Implications for cancer immunotherapy targets
We next focused on how antitumor immunity impacts




Fig. 4 Potential causes of inter-tumor immune infiltration heterogeneity. a In selected cancer types, counts of total somatic coding mutations
positively associated with the level of infiltrating immune cells. The y-axis is the residual of corresponding immune cell abundance after linear
regression against tumor purity. Statistical significance was evaluated using partial Spearman’s correlation adjusted for tumor purity. The asterisk
indicates only HPV-negative tumors were selected for head and neck cancer. Multiple test correction was performed across cancer types and six
immune components. Gray hues indicate previously known results (HNSC, LGG, and LUSC), while other findings are novel in this study. b CD8
T-cell infiltration is associated with microsatellite instability (MSI) status in cancers commonly with MSI. MSI-H high level of microsatellite instability,
MSI-L low level of microsatellite instability; MSS microsatellite stable. Statistical significance was evaluated using a Wilcoxon rank sum test. c, d
Chemokine/receptor networks for immune infiltration in diverse cancer types. Vertexes are ligands (green) and receptors (purple) and edges indicate
known molecular interactions. For each cancer, the partial correlations (corrected for purity) between the chemokine gene expression and infiltration
of CD8 T cells (c) or macrophages (d) were calculated. For a pair of interacting chemokine and receptor genes, if both are significantly correlated with
immune cell infiltration in one cancer, a colored dot represents the cancer type is placed on the edge connecting the chemokine and receptor.
Statistical significance was evaluated using partial Spearman’s correlation at a false discovery rate threshold of 0.01. Heatmap visualizations of the same
results are shown in Additional file 1: Figure S6c, d
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cancer/testis (CT) genes [6, 30] for their association with
immune components. MAGEA3 is an antigen that has
been tested in cancer vaccines, although it failed to dem-
onstrate improved progression-free survival in random-
ized non-small cell lung carcinoma clinical trials [31].
To explore the potential cause, we examined TCGA
gene expression data in lung cancer. MAGEA3 is not
expressed in adenocarcinoma but is expressed in squa-
mous cell carcinoma (Pearson’s correlation with purity
>0.1, q < 0.1), although MAGEA3 expression in the latter
is negatively associated with CD8 T-cell infiltration
(Fig. 5a, b). One possible interpretation of these results
is that the host immune system in lung cancer patients
fails to recognize MAGEA3 as a neoantigen, which
might explain the ineffectiveness of MAGEA3-based
vaccines in lung cancer. In contrast, clinical trials of
MAGEA3 have been more successful in melanoma [31],
consistent with our observed positive correlation be-
tween MAGEA3 expression and CD8 T-cell abundance
(Fig. 5c). Another positively correlated antigen in melan-
oma is the CT gene NY-ESO-1 (CTAG1B), which was re-
ported to be an effective vaccine antigen in a recent
study [32]. We also studied prostate cancer, for which
there is a US Food and Drug Administration-approved
cell-based cancer vaccine, sipuleucel-T. As expected,
many CT genes positively associate with CD8 T-cell
level, implying strong host immune reactions to cancer
antigens (Additional file 1: Figure S7). These observa-
tions suggest that association with infiltrating immune
cells could be a useful criterion for selecting putative
cancer vaccine targets, although the utility of this criter-
ion awaits future experimental validation. Based on this
hypothesis, we prioritized a list of CT genes in each can-
cer type through associations with infiltrating immune
cells (Additional file 5: Table S4). This analysis suggested
SPAG5 as a potential candidate for future vaccine devel-
opment in melanoma, glioma, prostate, bladder, breast,
and head and neck cancers (Fig. 5c; Additional file 1:
Figure S7). In TCGA, the median SPAG5 expression in
prostate, bladder, breast, and head and neck cancers
(where normal tissues are available) is at least threefold
over normal, suggesting that SPAG5 is a potentially valid
CT antigen in those cancer types. We have made these
results available in TIMER and users can check the rela-
tionships between a given CT antigen and the levels of
tumor infiltrating immune cells in different cancer types.
In addition to known CT genes, we applied the same
analysis procedures to a total of 2094 cancer-specific
genes (“Methods”) for their expression associations with
CD8 T-cell infiltration (Additional file 1: Figure S8;
Additional file 6: Table S5). Ranked by the number of
cancers for which this association is observed, the top
100 genes are most enriched in the gene ontology term
“cell cycle” (false discovery rate (FDR) = 4.74 × 10−24),
Fig. 5 Association of immune cell infiltration and cancer/testis (CT) antigen expression in non-small cell lung carcinomas (a-b) and melanoma (c).
Only genes with expression levels positively correlated with tumor purity (Pearson’s r > 0.1, q < 0.1) were selected to ensure cancer cell-specific expression.
The heatmap presents correlations of gene expression and tumor infiltrating immune cells, which were calculated using partial Spearman’s correlation
correcting for tumor purity. Asterisks indicate events significant at a 15 % FDR. Red arrowheads point to MAGEA3
Li et al. Genome Biology  (2016) 17:174 Page 8 of 16
consistent with a previous report that expression of cell
cycle genes upregulates immune infiltration [33].
The recent clinical success of checkpoint blockade
drugs in treating metastatic melanoma [1] is an exciting
development but predictive biomarkers are needed. In
order to find promising targets in diverse cancer types,
we examined how tumor-infiltrating immune cells cor-
relate with inhibitory molecules, including the receptors
CTLA4, PD-1, LAG3, and TIM3, and the ligands PD-L1/
2, B7-H3/4. We noticed that the abundance of CD8 T
cells correlates with the expression levels of inhibitory
receptors in almost all cancers (Additional file 1: Figure
S9a), indicating that inhibitory receptors are expressed
in the infiltrating T cells of most tumor sites at the time
of clinical intervention. We next investigated the poten-
tial cell sources of the inhibitory ligands. PD-L1/2 and
B7-H3 expression positively correlates with macrophage
infiltration in almost all cancers, suggesting TAM as a
source of these ligands. The same is true for B7-H4 ex-
cept for gliomas (GBM and LGG), rectal cancer, and
melanoma (Additional file 1: Figure S9b). In LGG and
cervical cancer, further analysis reveals that B7-H4 is
expressed primarily in cancer cells (Additional file 1:
Figure S9c). These findings might help identify alterna-
tive therapeutic options in different cancers.
Although effective in a subset of patients, checkpoint
blockade drugs usually have moderate response rates
[31]. To explore possible explanations for the varied
clinical responses, we studied the levels of inhibitory re-
ceptors and CD8 T-cell infiltration within each cancer
type. Unexpectedly, we found that CTLA4 expression in
melanoma differentially correlates with CD8 T-cell levels
in different tumors (Fig. 6a). In a subset of high purity




Fig. 6 Varied levels of CD8 T-cell infiltration in tumors highly expressing inhibitory receptors. a, b High CTLA4/TIM3-expressing tumors in melanoma/
KIRC show different CD8 T-cell infiltration levels. Dashed lines in both panels are the hypothetical high CTLA4 or TIM3 cutoff. Tumor purity is indicated
by color. Arrows in b point to selected TCGA samples for immunohistochemistry (IHC) analysis. c Sample with low TIM3 expression and CD8 T-cell
infiltration used as a negative control. TIM3- or CD8-expressing cells are brown in color. Selected samples with (1) high TIM3 expression and (2) low (d)
or high (e) CD8 T-cell infiltration showed the existence of two KIRC sample groups. TIM3 expression in d is twice as high as in e according to RNA-seq
data. d Image represents about 15 % TCGA KIRC samples while e represents 5 %. The upper and lower panels were synchronized. TIM3 was expressed
in cancer cells (d, e) as well as in lymphocytes (e). High magnification insets are presented in d and e to illustrate TIM3 expression in different cell types.
Yellow boxes indicate lymphocytes; red boxes indicate tumor cells
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CD8 T cells. The same phenomenon holds for renal
clear cell cancer, where tumors with high TIM3 expres-
sion have varying CD8 T-cell levels (Fig. 6b). Since anti-
bodies that allow immunohistochemical staining of
CTLA4 were unavailable, we sought to experimentally
validate the levels of TIM3 and CD8 T-cell infiltration.
A subset of the TCGA renal tumors was submitted lo-
cally and remaining tissue slides were available for these.
Staining of selected renal tumors (Fig. 6c–e) confirmed
that TIM3 is expressed on cancer cells as well as infil-
trating lymphocytes (Fig. 6e), an observation recently re-
ported [34]. More importantly, we found that tumors
with high TIM3 expression can be divided into two dis-
tinct groups with different levels of infiltrating CD8 T
cells (Fig. 6d, e; Additional file 1: Figure S10). Melanoma
and kidney cancer with high expression of inhibitory re-
ceptors and low levels of CD8 T-cell infiltration may
have different clinical responses to checkpoint blockade
drugs compared with tumors with high CD8 T-cell infil-
tration, a hypothesis that awaits further testing.
Discussion
With the clinical success of cancer immunotherapies,
there is a growing need for a comprehensive under-
standing of tumor–immune interactions. In this study,
we developed a novel method for tumor immune cell de-
convolution and have provided a comprehensive catalog
of the abundance of six immune infiltrates in 23 cancer
types. Our method was validated using Monte Carlo simu-
lations, orthogonal estimates from DNA methylation-
based inferences, as well as pathological assessment.
Further validations using immunohistochemistry (IHC)
or cell sorting are infeasible since TCGA does not pro-
vide original tumor samples. We have made our esti-
mated immune cell abundance together with associated
findings available as a public resource, TIMER, for bio-
medical researchers to address more interesting ques-
tions in cancer immunology. The information covered
in this work was accessible through a user-interactive
website (http://cistrome.org/TIMER).
Our work first provided a systematic prognostic land-
scape of different tumor-infiltrating immune cells in di-
verse cancer types. We compared our results with two
recent studies on the same topic [6, 11]. The method
used in Gentles et al., CIBERSORT [35], is currently only
applicable to microarray data, thus unable to analyze the
TCGA RNA-seq data. Therefore, our immune compo-
nent estimation is a unique addition to TCGA for future
integrative analyses of tumor–immune interactions. By
including more immune cell types into regression,
CIBERSORT inference also suffered from statistical co-
linearity that might have resulted in biased estimations
(Additional file 7: Table S6; Additional file 8). Due to
this limitation, although Gentles et al. studied more cell
types, they reported few significant prognostic immune
predictors, without correction for other clinical con-
founders. In contrast, we observed many more signifi-
cant clinical associations with the correction of
multiple cofactors. It should be noted that due to lim-
ited sample size, some of these associations only
reached a FDR of 0.15, yet 85 % of these significant
calls are expected to be true and still be informative.
These observations include both established results
from previous clinical studies as well as novel ones that
may provide new angles to study the clinical responses
of immunotherapies.
We then demonstrated the usefulness of TIMER by
studying putative immunotherapy targets and made sev-
eral interesting observations. First, CD8 T-cell and
macrophage infiltration is likely to be regulated by differ-
ent sets of chemokine and chemokine receptors in
different cancers. Second, the effectiveness of cancer
vaccine targets might be predicted via association with
immune infiltration levels; based on our data, it appears
that SPAG5 is a potential vaccine candidate for multiple
cancers. Third, the correlation of CTLA4 and PD-1 ex-
pression with CD8 T-cell abundance suggests that a sub-
set of patients from most cancer types may benefit from
combined use of anti-CTLA4 and anti-PD-1 agents. Fi-
nally, CTLA4 and TIM3 expression fall in distinct groups
relative to CD8 T-cell infiltration in melanoma and kid-
ney cancer, respectively, which might contribute to the
varied clinical response to checkpoint blockade therap-
ies. Although detailed characterization of the underlying
mechanisms requires further work, the findings from
this study have immediate implications for cancer
immunotherapies.
The current release of TIMER is based on estimations
using transcriptome profiles (RNA-seq or microarray)
from whole tissues at a single time point. Consequently,
TIMER might have limited relevance to distinguish stro-
mal or intra-tumor immune cell localization or capture
tumor cell heterogeneity. In the future, we anticipate
more experimental measures with improved spatial and
temporal resolutions, and the applicability of TIMER
should continue to grow as we make inferences on new
datasets and incorporate them into the existing
resources.
Conclusions
In this study we systematically documented the abun-
dance of six tumor-infiltrating immune compartments for
TCGA samples and integratively analyzed the immune in-
filtration with other cancer molecular profiles. We identi-
fied widespread clinical associations of different immune
cell types in multiple cancers. Systematic exploration of
tumor–immune interactions revealed cancer genetic alter-
ations and chemokine/receptor expression networks are
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potential regulators of immune cell infiltration heterogen-
eity. Our analyses on putative immunotherapy targets led
to the findings on cancer vaccine candidate SPAG5 and
dichotomized CD8 T-cell levels in tumors highly express-
ing inhibitory receptors. Our results add value to the
current knowledgebase of tumor immunity and provide a
public resource for further exploration of cancer–immune
interactions.
Methods
Data collection and preprocessing
Molecular data for 23 TCGA cancer types, including
level 2 DNA SNP array and clinical data, were down-
loaded from TCGA data portal (https://gdc.nci.nih.gov)
and level 3 mRNA expression data from the GDAC
Firehose website (http://gdac.broadinstitute.org). For
all cancers but GBM or OV, whole transcriptome
RNA-sequencing (RNA-seq) data were available and
we used the RSEM-processed transcript per million
(TPM) measure. For GBM and OV, where RNA-seq
data were available for only a subset (approximately
one-third for GBM and one-half for OV) of samples,
we used microarray data profiled using Affymetrix
HGU133a platforms for immune component estimation
(Additional file 8). In this study, we found that the
HGU133a array could not accurately profile the lowly
expressed genes (including important therapeutic tar-
gets such as PD-1). Therefore, we applied RNA-seq data
for GBM and OV to study the immunotherapy targets
(Fig. 5; Additional file 1: Figures S7 and S9). We used
the Human Primary Cell Atlas (HPCA) [36] as the ref-
erence dataset of gene expression profiles of sorted im-
mune cell types. HPCA is a collection of previous
analyses on human primary cells using the Affymetrix
HGU133plus2 platform and includes more than 100
studies, which are numbered in the dataset. We selected
six immune cell types for our downstream analysis and
the studies used for each cell type are: 25, 45, and 115
for B cells; 12, 42, 76, and 115 for CD4 T cells; 42, 115,
and 116 for CD8 T cells; 39, 62, and 77 for neutrophils;
104 for macrophages; and 7, 9, 14, 28, 86, 89, 91, and
103 for dendritic cells. A complete list of reference sam-
ples is available in Additional file 9: Table S7. It should
be noted that each immune cell type still represents a
mixed population with cells of potentially distinct func-
tions. For example, CD4 T cells may include helper T
cells, memory T cells, and regulatory T cells and B cells
may represent a mixture of mature CD19 B cells and B
plasma cells. In this study, we do not seek to further
distinguish these subpopulations, as their expression
profiles are highly similar. Signature genes (n = 2271,
denoted as Gi) overexpressed in the immune lineage
were obtained from the Immune Response In Silico
database [18].
Inclusion criteria for immune cell types
In order to minimize co-linearity in the regression ana-
lysis and maximize the robustness of our inference, our
study focused on six immune components based on two
criteria. First, the reference data contain at least ten in-
dependent samples of the immune cell type. Second, if
the expression profile of a given cell type is highly corre-
lated (sample-wise Pearson’s r ≥ 0.9) with other cell
type(s), we chose the cell type with more samples. The
selected cell types represent the finest resolution of im-
mune cell lineages that we can achieve based on the
above inclusion standards. Cell types excluded from the
inference may affect the highly correlated immune com-
ponents included. Improved reference immune datasets
will be needed to deconvolve individual cell types.
Computational method for immune cell composition
deconvolution
We first estimated sample purity for each tumor through
DNA SNP array data using our previously developed
tool CHAT [15]. Genomic estimations of tumor purity
have been validated using diluted series of cancer and
blood cell lines with known mixture ratios [16]. To clar-
ify, the quantity inferred from CHAT is the fraction of
aneuploid cells. In this work, we used this quantity as a
surrogate of tumor purity. Samples with percent on
point (PoP) <0.01 were excluded, where PoP is a quality
measure reported by CHAT. In each cancer, we selected
genes with expression values negatively correlated with
tumor purity (Pearson’s r ≤ −0.2, P ≤ 0.05), denoted as
Gp, and intersected with Gi. Our goal in this step is to
select informative genes with expression levels strongly
affected by tumor purity. It is not important whether the
gene is highly or lowly expressed. Pearson’s correlation
is suitable because it is a measure of the linear depend-
ence of two random variables, disregarding the magni-
tude of the observations. The resulting smaller gene set
intersection was denoted as G0, which is cancer-type
specific. Meanwhile, we merged the tumor gene expres-
sion with the reference immune cell data of all genes
using ComBat [17]. According to the principal compo-
nents analysis plot, ComBat effectively removed the
batch effect between different datasets generated using
different platforms (Fig. 1b). For each of the six cell
types, we then calculated the median expression value in
all the samples available for that cell type for each gene
in G0. The resulting dataset (referred to as R) contains
six vectors of gene expression values, each for one cell
type. We used R to filter G0 in the following way: for
each vector in R, genes with expression values in the top
1 % in G0 are removed. This is because genes expressed
at extremely high levels in the reference dataset will
dominate the inference results. Since highly expressed
genes have large variance, our inferences become very
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sensitive to these outliers. We therefore remove them to
acquire more robust estimations. The total removed
genes were the union of the top 1 % from of the six vec-
tors. The resulting gene set was denoted as G0f. For each
sample, a constrained least square fitting described in a
previous study [19] was applied to infer the relative
abundance for each of the six immune components
(Fig. 1e). The predictions of this method were validated
using mixtures of different blood cell types with known
ratios. For a given sample, let Yg denote the gene expres-
sion of gene g, where g ∈ G0f. Let X
g
r denote the gene ex-
pression of gene g in immune cell type r (r = 1,2,…,6) in
reference dataset R. Since we model that the given sam-
ple is a mixture of the six immune cell types, our task is













which is a constrained linear regression problem. The
estimation accuracy of f should be affected by the genes
used in the fitting, although our model assumes that
such an f exists and should be the same for all genes.
To note, coefficients f estimated using this method are
the relative abundance of immune cells. The scale of
the estimation of an individual immune cell type is de-
termined by the variance of the corresponding refer-
ence data Xr. Therefore, f are not comparable between
cancer types or different immune cells. Source codes
for TIMER and downstream statistical analysis as well
as related data files are available at http://cistrome.org/
TIMER/download.html.
Correction for reference immune cell colinearity
Although the six immune cell types in this study are se-
lected in such ways that the colinearity between cell
types is minimized, we found that in THCA and UCS,
CD4 and CD8 T-cell signatures are still very similar.
Consequently, the inferred CD4 and CD8 T-cell levels
are negatively correlated (Pearson’s r ≤ −0.3), which is
an artifact of covariates’ colinearity in the constraint re-
gression. Additional analysis on these two cancers re-
vealed that the negative correlation is driven by a small
number of CD4 or CD8 T-cell signature genes that are
extremely overexpressed in the tumor samples. We re-
move the union of the top expressed gene in each
tumor sample and re-estimate f. This step is repeated
until the correlation between estimated CD4 and CD8
T-cell levels is larger than −0.3. This analysis provides
more robust estimations of immune cell abundance in
cancer types.
Pathological estimation of neutrophil infiltration in BLCA
For the TCGA data sets, the original samples are unavail-
able for further studies; however, hematoxylin and eosin
(H&E) digital slides have been publicly released. While it is
not possible to distinguish T cells and B cells by H&E, neu-
trophils are morphologically distinctive and their abun-
dance can be estimated. Occasional dendritic cells and
macrophages can be identified by H&E but their true
abundance is difficult to estimate in the absence of immu-
nohistochemical stains. Slides were reviewed via digital im-
ages viewed with the Cancer Digital Slide Archive (http://
cancer.digitalslidearchive.net). We chose BLCA because it
has a large sample size (n = 404), does not have excessive
necrosis, and has sufficient neutrophil counts and sample
variety to allow for validation by histological evaluation.
The pathologist reviewing the slides was blinded to the in
silico neutrophil predictions. Samples were stratified into
three groups (high, medium, low) with levels of neutro-
phils relative to the entire collection of samples.
DNA methylation-based total leukocyte estimation
The percentage of total DNA for each tumor was esti-
mated using DNA methylation data as previously de-
scribed and compared with purity estimates derived from
SNP data [20, 37]. In brief, the estimates were derived
from loci with tissue-specific methylation that distin-
guishes the corresponding tissue type from lymphocytes
using the TCGA Pancan12 [38] DNA methylation dataset.
The leukocyte methylation signature was derived as fol-
lows. Each probe was ranked by the difference in mean
beta value in buffy coat and corresponding normal sam-
ples. We retained the 100 probes with the largest positive
difference and the 100 with the largest negative difference
between mean DNA methylation in normal tissues and
peripheral blood leukocytes, designated NT and BC probes
(hypermethylated in normal tissue compared with buffy
coat, and vice versa, respectively). Let Tik denote the beta
value for probe k in tumor sample i. Let Bk denote the
average beta value of buffy coat samples for each probe.
Let Tk denote the minimum observed beta value across all
tumor samples for the BC probes and the maximum for
the NT probes, which theoretically reflects the ground
state of methylation level in the purest tumor. Denote
with fB the fraction of buffy coat (leukocyte) components
in the sample, then, assuming a linear relationship, we
have the following equation for each probe:
Tik ¼ BkfB þ Tk 1 − fBð Þ
Solving this equation for fB gives:
fB ¼ Tik− Tkð Þ= Bk− Tkð Þ
The values of fB for each of the 200 probes in the
signature were calculated and a kernel density estimate
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of fB was obtained. The leukocyte signature was then
calculated as the mode of this density estimate.
Monte Carlo sampling and in silico validation
We validated our predictions on infiltrating immune cell
abundance using in silico simulated data. As mentioned,
for each cancer we selected a gene set G0f (length n0) for
least squares fitting. In order to control for the mixing
ratios of the six components while maintaining the cor-
relation structure of the real data, we first calculate the
gene–gene covariance matrix Σ0f for all the genes in G0f
using tumor expression data. We then randomly sample
six numbers f1-6, from Uniform(0,1). We calculate μ0f
(length n0), which is the average of six immune compo-
nents weighted by f1-6. Next, we sample a vector of
length n0 from multivariate normal distribution with
mean μ0f and covariance Σ0f. For each cancer type, we
simulated the same number of samples as its sample size
in the TCGA data. After applying our method, we com-
pared the estimated immune abundance with true values
using Pearson’s correlation. Low quality estimations with
Pearson’s r ≤ 0.2 were excluded from the downstream
analysis.
Selection of cancer specific genes
For each cancer type, we compare tumor samples with
all normal samples collectively. Only genes overex-
pressed in tumor samples and absent or expressed at
lower levels in all normal tissues were selected. Differen-
tially expressed genes were selected based on a FDR
≤0.05 and at least a twofold difference in expression
levels. In the case of tumors with established clinical
subtypes, such as breast cancer, we selected the top 25
samples for each gene based on their rank of raw read
counts, then identified differentially expressed genes
within each subtype. The final tumor-specific gene set
was the union of all the cancer types (or subtypes).
Statistical analysis
Multivariate Cox regression, log-rank test and Kaplan–
Meier estimators were implemented using the R package
survival. The association between CD8 T-cell abundance
and tumor status was evaluated using logistic regression
corrected for age and clinical stage and was imple-
mented using the R package glm. The same analysis was
performed for neutrophil abundance and gender associa-
tions, corrected for age and smoking history. Partial cor-
relations of immune cell abundance and gene expression
of chemokines and receptors, somatic mutation counts,
CT gene expression, as well as immunosuppressive mol-
ecule expression were calculated using the R package
ppcor. Multiple test correction was performed using the
R package qvalue [39] and FDR thresholds are applied
based on the abundance of signals in the data. In this
study, we applied the Pearson correlation to purity and
gene expression because it is reasonable to expect that
the expression level is linearly associated with tumor
purity. For others, we used the Spearman correlation.
We applied partial correlation analysis to remove the in-
fluence of tumor purity on the involved variables. All
other analyses, including linear regression, Fisher’s exact
test, Wilcoxon rank sum test, Spearman’s correlation,
and hierarchical clustering, were performed using R [40].
Of note, in Figs. 2b and 3b, we used the 20 percentile as
a cutoff only to help visualize the association of immune
infiltration with outcomes and the statistical significance
was determined by multivariate Cox regression (Fig. 3a)
including all the samples. Our results on survival ana-
lysis, neoantigen association, tumor recurrence, and as-
sociation of checkpoint blockade inhibitory molecules
with immune cells are available in Additional file 10:
Table S8.
Additional analysis on HNSC and SKCM
One intriguing result we observed is that univariate and
multivariate survival analysis results for HNSC and
SKCM are not consistent (Fig. 3a, b). For HNSC, we dis-
covered that HPV infection, a recently identified prog-
nostic factor [41], correlates with CD8 T-cell infiltration
(Additional file 1: Figure S4). It is likely that the previ-
ously observed association of CD8 T cells with survival
is contributed to by virus infection. On the other hand,
for SKCM, we found that the infiltration level of CD8 T
cells is highly correlated with neutrophils (Pearson’s r =
0.79) and dendritic cells (r = 0.81), indicating that these
immune cells work in concert. As highly correlated fea-
tures confound each other in a multiple regression, we
performed principal component analysis on the abun-
dance of the six immune cells. We reanalyzed the Cox
model using six principal components (PCs), age and
stage as covariates, and found PC1 (hazard ratio (HR) =
2.6 × 10−4, p = 0.0062), PC4 (HR = 1.07 × 102, p = 0.033)
and PC6 (HR = 0.01, p = 0.008) to be significantly associ-
ated with survival. PC1 was comprised of CD8 T cells,
neutrophils, and dendritic cells (by Pearson’s correl-
ation), thus capturing the colinearity in the data. PC4
represented macrophages and predicted worse outcome.
There was no clear assignment of PC6 to any immune
component(s) and it may represent an unselected im-
mune cell type.
Additional analysis on OV and BRCA
In the survival analysis (Fig. 3a, b), we failed to identify
some known prognostic predictors, notably B cells in
OV and CD8 T cells in BRCA. A previous study reported
that CD20 cells positively associate with survival [42].
We investigated the expression levels of the B-cell
markers CD19 and CD20 in OV and discovered that
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tumor purity is not negatively correlated with gene ex-
pression levels for both genes, indicating that aneuploid
cells in ovarian cancer may also express B-cell markers.
Therefore, cell sorting based on CD19 or CD20, which is
not the B-cell component in our analysis, is likely to se-
lect cancer cells. CD8 T cells were previously reported to
associate with better outcome in BRCA [43], although
we did not observe this relationship. This is possibly due
to insufficient follow-up time or fewer deaths in the
TCGA BRCA data, which thus underpowered our sur-
vival analysis.
Patient samples for IHC
De-identified clear cell renal cell carcinoma (ccRCC)
formalin-fixed and paraffin-embedded tissue blocks from
cases included in the TCGA KIRC cohort were obtained
from the department of Pathology at the Brigham and
Women’s Hospital. Patients had provided an informed
consent for use of specimens and baseline and prospective
clinical data for research purposes. The study was ap-
proved by the Dana-Farber/Harvard Cancer Center
(DF/HCC) institutional review board. In total, five
TCGA samples were selected for IHC: TCGA-CZ-5453-
01A (negative control), TCGA-CZ-4866-01A, TCGA-CZ-
4863-01A, TCGA-CZ-5459-01A, and TCGA-CZ-4862-
01A.
IHC protocol
IHC for TIM3 and CD8 expression was performed as
described below. For TIM3 IHC, rehydrated tissue sec-
tions were boiled in EDTA buffer (pH 8) with a micro-
wave at 92 °C for 30 minutes. After cooling down at
room temperature (RT), tissue sections were successively
incubated with a peroxidase block (Dual Endogenous
Enzyme Block, Dako) and a protein block (Serum Free
Block, Dako) for 10 minutes each. Sections were next in-
cubated for 1 h at RT with the goat polyclonal anti-
TIM3 antibody (1/400, AF2365, R&D Systems) diluted
in Da Vinci Green Diluent (Biocare Medical). Tissue
sections were then incubated with a rabbit anti-goat
biotin-conjugated antibody (1/750, Dako) for 30 minutes
followed by an incubation of 30 minutes with EnVision
anti-rabbit horseradish peroxidase (HRP)-conjugated
antibody (Dako). The HRP visualization was performed
by applying 3,3-diaminobenzidine substrate (Dako) for
5 minutes. Nuclei were counterstained with hematoxylin.
For CD8 staining, rehydrated tissue sections were boiled
in EDTA buffer (pH 8) with a pressure cooker at 125 °C
for 30 s. Sections were blocked as described above and
then incubated for 1 h at RT with a mouse monoclonal
anti-CD8 antibody (1/100, clone C8/144B, Dako) diluted
in Antibody Diluent with Background Reducing Compo-
nents (Dako). Sections were then incubated with EnVision
anti-mouse HRP-conjugated antibody for 30 minutes
(Dako). The HRP visualization and the counterstaining
were performed as described above.
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